内皮细胞而非全身性铁死亡抑制可预防ANCA诱导的新月体性肾小球肾炎
本研究探讨铁死亡在ANCA相关性血管炎(AAV)肾小球肾炎中的作用。体外实验显示ANCA激活的中性粒细胞诱导内皮细胞铁死亡,铁死亡抑制剂可阻止该过程;内皮细胞特异性ACSL4敲除小鼠在MPO-AAV模型中显示肾脏保护,但全身性铁死亡抑制未能保护小鼠,且Ferrostatin-1可激活T细胞增殖。
要点
- 内皮细胞铁死亡参与ANCA诱导的新月体性肾小球肾炎。
- 内皮细胞特异性ACSL4缺失可保护小鼠免受NCGN。
- 全身性铁死亡抑制未显示保护,可能与T细胞激活有关。
核心结论
- 内皮细胞铁死亡促进ANCA诱导的新月体性肾小球肾炎。
- 全身性药理铁死亡抑制未能预防小鼠AAV模型中的NCGN,不建议开展临床研究评估该策略。
研究设计与样本
- 体外实验:ANCA激活的中性粒细胞诱导内皮细胞死亡,使用铁死亡抑制剂及ACSL4 siRNA干预。
- 体内实验:构建内皮细胞特异性ACSL4敲除(ACSL4ΔEC)小鼠,在MPO-AAV骨髓移植模型中评估NCGN。
- 药理实验:在鼠AAV模型中使用Ferrostatin-1或Liproxstatin-1进行全身性铁死亡抑制。
主要发现
- Ferrostatin-1、Liproxstatin-1及抗ACSL4 siRNA可阻止ANCA激活中性粒细胞诱导的内皮细胞死亡;坏死性凋亡和凋亡抑制均无效。
- Ferrostatin-1和Liproxstatin-1减轻内皮细胞脂质过氧化物积累;AAV小鼠肾切片免疫组化显示脂质过氧化增加。
- ACSL4ΔEC嵌合小鼠在MPO-AAV骨髓移植模型中免受NCGN,而对照(ACSL4WT)小鼠未受保护。
- Ferrostatin-1或Liproxstatin-1全身性给药在鼠AAV模型中未保护NCGN。
- Ferrostatin-1在体外直接激活T细胞增殖,并间接通过髓系介导T细胞增殖和极化。
临床怎么用
- 内皮细胞铁死亡是AAV肾小球肾炎的潜在机制,但全身性铁死亡抑制可能因免疫激活效应而抵消保护作用。
- 不应在临床AAV研究中评估全身性药理铁死亡抑制策略,需探索内皮靶向干预。
局限性
- 全身性铁死亡抑制的失败可能与Ferrostatin-1激活T细胞增殖有关,机制尚未完全阐明。
- 研究结论主要基于小鼠模型和体外实验,临床转化需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are systemic autoimmune diseases featuring small blood vessel inflammation and organ damage, including necrotizing crescentic glomerulonephritis (NCGN). Persistent vascular inflammation leads to endothelial and kidney cell necrosis. Ferroptosis is a regulated cell death pathway executed by reactive oxygen species and iron-dependent lipid peroxidation culminating in cell membrane rupture. Here we show that ANCA-activated neutrophils induced endothelial cell (EC) death in vitro that was prevented by ferroptosis inhibition with Ferrostatin-1, Liproxstatin-1 and small inhibiting RNA against the enzyme AcylCoA Synthetase Long Chain Family Member 4 (ACSL4). In contrast, neither necroptosis nor apoptosis inhibition affected EC death. Moreover, both ferroptosis inhibitors alleviated lipid peroxide accumulation in EC. Increased lipid peroxidation was detected in kidney sections of AAV mice by immunohistochemistry. We generated MPO-/- ACSL4flox Tie2-Cre+ mice lacking ACSL4 specifically in EC (ACSL4ΔEC) to study the significance of endothelial ferroptosis in vivo. ACSL4ΔEC chimeric mice, but not control mice (ACSL4WT), were protected from NCGN in an MPO-AAV bone-marrow transplantation model. These data establish that EC ferroptosis contributes to ANCA-induced glomerulonephritis. However, systemic pharmacological ferroptosis inhibition with Ferrostatin-1 or Liproxstatin-1 did not protect from NCGN in a murine AAV model. Ferrostatin-1 treatment both directly activated T-cell proliferation and indirectly myeloid-mediated T-cell proliferation and polarization in vitro. Conceivably, both effects may cancel the beneficial effect of endothelial ferroptosis inhibition. Mechanistically, we describe the importance of EC ferroptosis for the development of AAV. However, the lack of protection with systemic pharmacological ferroptosis inhibition should discourage clinicians from evaluating this treatment strategy in clinical AAV studies.
引用
- Rousselle A, Lodka D, Sonnemann J, et al. Endothelial but not systemic ferroptosis inhibition protects from antineutrophil cytoplasmic antibody-induced crescentic glomerulonephritis. Kidney Int. 2025. PMID: 40122342. doi:10.1016/j.kint.2025.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。